text: E-AB sensors can be adapted into wearable devices that monitor health of patients in real time. E-AB sensors are capable of monitoring specific biomarkers that can aid in detection of diseases in early stages. For example, the measurement of C-reactive protein can aid in detection of heart attacks on a wearable device.
  E-AB sensors offer groundbreaking possibilities for monitoring molecules within the intricate in-vivo environment, with transformative applications in clinical settings. Envisioning the integration of the E-AB sensing platform into a wearable device, comparable to continuous glucose monitors, holds promise for real-time measurements of drugs and biomarkers reflective of health and disease. Notably, exploring E-AB sensors in the interstitial skin region shows potential in this regard.
  In instances where sepsis is suspected, the monitoring of infection biomarkers, such as C-reactive protein, stands out as a potentially life-saving approach, providing critical insights into disease prognosis and severity. Similarly, for individuals at high cardiac risk, the deployment of a convenient wearable device could facilitate early detection of heart attacks, considering the association of specific biomarkers like troponin with the onset of cardiac events. The exceptional capability of E-AB sensors to measure picomolar concentrations of specific proteins in real-time within complex sample matrices positions the platform as a well-suited tool for such clinical monitoring applications.
  Expanding beyond disease detection, E-AB sensors hold the promise of revolutionizing drug dosing practices, particularly in the realm of precision medicine. The prevalent approach to pharmaceutical dosing, grounded in assumptions about the average individual's drug absorption and response, falls short for drugs with narrow therapeutic windows relative to patient variability. Current dosing methodologies, relying on slow and infrequent blood draws or waiting for observable side effects, entail potential risks of underdosing or overdosing. E-AB sensors, with their capability to provide real-time insights into plasma drug levels, present an avenue for significantly enhancing the safety and efficacy of pharmacological treatments through improved therapeutic drug monitoring.